{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:57:51Z","timestamp":1790495871696,"version":"4.1.0"},"reference-count":151,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["225481\/Z\/22\/Z"],"award-info":[{"award-number":["225481\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR302616"],"award-info":[{"award-number":["NIHR302616"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.autrev.2026.104095","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T23:39:20Z","timestamp":1779493160000},"page":"104095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Interleukin-17-T helper 17 axis in primary sclerosing cholangitis: A narrative review of an emerging pathogenic frontier"],"prefix":"10.1016","volume":"25","author":[{"given":"Amera","family":"Elzubeir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rushbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0005","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/HEP.0000000000001080","article-title":"Immunobiology of primary sclerosing cholangitis","volume":"82","author":"Cornillet","year":"2024","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2026.104095_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cld.1264","article-title":"Primary sclerosing cholangitis-a long night\u2019s journey into day","volume":"20","author":"Chapman","year":"2022","journal-title":"Clin Liver Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104095_bb0015","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104095_bb0020","article-title":"Past, current, and future trends in the prevalence of primary sclerosing cholangitis and inflammatory bowel disease across England (2015-2027): a nationwide, population-based study","volume":"44","author":"Crothers","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0025","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jhep.2008.02.017","article-title":"Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study","volume":"48","author":"Card","year":"2008","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104095_bb0030","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.cgh.2021.08.039","article-title":"Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies","volume":"20","author":"Trivedi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104095_bb0035","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/liv.15007","article-title":"Global incidence, prevalence and features of primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"41","author":"Mehta","year":"2021","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.autrev.2026.104095_bb0040","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0045","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","article-title":"Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities","volume":"55","author":"Vesterhus","year":"2020","journal-title":"J Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0050","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.mayocp.2015.03.017","article-title":"The cholangiopathies","volume":"90","author":"Lazaridis","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0055","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary Sclerosing Cholangitis - A comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104095_bb0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of Primary Sclerosing Cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0065","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-018-0620-2","article-title":"The IBD and PSC phenotypes of PSC-IBD","volume":"20","author":"Ricciuto","year":"2018","journal-title":"Curr Gastroenterol Rep"},{"issue":"12","key":"10.1016\/j.autrev.2026.104095_bb0070","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.dld.2021.04.028","article-title":"Treatment of Primary Sclerosing Cholangitis","volume":"53","author":"Floreani","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2026.104095_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/tgh-20-266","article-title":"Primary Sclerosing Cholangitis","volume":"6","author":"Rabiee","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104095_bb0080","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2019.05.095","article-title":"Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial","volume":"82","author":"Puig","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0085","article-title":"The IL-17 family in diseases: From bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.autrev.2026.104095_bb0090","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nri1784","article-title":"Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease","volume":"6","author":"Adams","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104095_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1160","article-title":"Sirtuin2 suppresses the polarization of regulatory T cells toward T helper 17 cells through repressing the expression of signal transducer and activator of transcription 3 in a mouse colitis model","volume":"12","author":"Ge","year":"2024","journal-title":"Immun Inflamm Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104095_bb0100","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/00042737-199907000-00015","article-title":"Immunohistochemical analysis of inflammation in primary sclerosing cholangitis","volume":"11","author":"Ponsioen","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104095_bb0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00628.x","article-title":"Th17 cells in human disease","volume":"223","author":"Tesmer","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2026.104095_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1279837","article-title":"Interactions between neutrophils and T-helper 17 cells","volume":"14","author":"Fan","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104095_bb0115","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2026.104095_bb0120","doi-asserted-by":"crossref","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet 2024;403(10443):2504-19. doi:https:\/\/doi.org\/10.1016\/s0140-6736(24)00101-6 [published Online First: 20240522].","DOI":"10.1016\/S0140-6736(24)00101-6"},{"issue":"11","key":"10.1016\/j.autrev.2026.104095_bb0125","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of Brodalumab in patients with moderate-to-severe Crohn\u2019s disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104095_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102647","article-title":"The role of TH17 cells in multiple sclerosis: therapeutic implications","volume":"19","author":"Moser","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0135","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/13543784.2024.2351505","article-title":"From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?","volume":"33","author":"Byravan","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"10.1016\/j.autrev.2026.104095_bb0140","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","article-title":"A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104095_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1437046","article-title":"Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease","volume":"15","author":"Abdelnabi","year":"2024","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104095_bb0150","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ni1496","article-title":"Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104095_bb0155","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2026.104095_bb0160","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/314620","article-title":"Th17 cell plasticity and functions in cancer immunity","volume":"2015","author":"Gu\u00e9ry","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.autrev.2026.104095_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.588436","article-title":"Intrahepatic T(H)17\/T(Reg) cells in homeostasis and disease-it\u2019s all about the balance","volume":"11","author":"Drescher","year":"2020","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104095_bb0170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/eci.11.96","article-title":"Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease","volume":"8","author":"Raza","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104095_bb0175","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.13280","article-title":"Cytokine-regulated Th17 plasticity in human health and diseases","volume":"163","author":"Cerboni","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2026.104095_bb0185","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8816041","article-title":"Th17 cells in inflammatory bowel disease: cytokines, plasticity, and therapies","volume":"2021","author":"Zhao","year":"2021","journal-title":"J Immunol Res"},{"issue":"2","key":"10.1016\/j.autrev.2026.104095_bb0190","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s10875-010-9368-7","article-title":"Th17 cytokines and the gut mucosal barrier","volume":"30","author":"Blaschitz","year":"2010","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14964","article-title":"Physiological roles of human interleukin-17 family","volume":"33","author":"Liu","year":"2024","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2026.104095_bb0200","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104095_bb0205","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nri2800","article-title":"Innate IL-17-producing cells: the sentinels of the immune system","volume":"10","author":"Cua","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0210","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.autrev.2026.104095_bb0215","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104095_bb0220","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/345803","article-title":"Role of IL-17 and Th17 cells in liver diseases","volume":"2011","author":"Hammerich","year":"2011","journal-title":"Clin Dev Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104095_bb0225","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.autrev.2018.06.008","article-title":"IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases","volume":"17","author":"Beringer","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0230","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.4049\/jimmunol.0901216","article-title":"Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver","volume":"184","author":"Oo","year":"2010","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104095_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23115872","article-title":"Interplay between mast cells and regulatory T cells in immune-mediated Cholangiopathies","volume":"23","author":"Krajewska","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0240","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2026.104095_bb0245","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s10620-014-3438-2","article-title":"Depletion of Foxp3+ regulatory T cells promotes profibrogenic milieu of cholestasis-induced liver injury","volume":"60","author":"Roh","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"7559","key":"10.1016\/j.autrev.2026.104095_bb0250","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature14452","article-title":"Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation","volume":"523","author":"Gagliani","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.autrev.2026.104095_bb0255","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1097\/MIB.0b013e3182a85709","article-title":"Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients","volume":"19","author":"Ueno","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104095_bb0260","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","article-title":"Human IL-17: a novel cytokine derived from T cells","volume":"155","author":"Yao","year":"1995","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104095_bb0265","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104095_bb0270","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.71.1.1","article-title":"IL-17: prototype member of an emerging cytokine family","volume":"71","author":"Aggarwal","year":"2002","journal-title":"J Leukoc Biol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104095_bb0280","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.molmed.2016.01.001","article-title":"IL-17 in chronic inflammation: from discovery to targeting","volume":"22","author":"Beringer","year":"2016","journal-title":"Trends Mol Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104095_bb0285","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104095_bb0290","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"10.1016\/j.autrev.2026.104095_bb0295","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1074\/jbc.M700499200","article-title":"Identification of an interleukin 17F\/17A heterodimer in activated human CD4+ T cells","volume":"282","author":"Wright","year":"2007","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0300","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","article-title":"Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses","volume":"30","author":"Ishigame","year":"2009","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.autrev.2026.104095_bb0305","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104095_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104095_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00647","article-title":"Interleukin-25 produced by synoviocytes has anti-inflammatory effects by acting as a receptor antagonist for interleukin-17A function","volume":"8","author":"Lavocat","year":"2017","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104095_bb0320","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ni.2156","article-title":"IL-17C regulates the innate immune function of epithelial cells in an autocrine manner","volume":"12","author":"Ramirez-Carrozzi","year":"2011","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0325","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/prd.12083","article-title":"Basic biology and role of interleukin-17 in immunity and inflammation","volume":"69","author":"Zenobia","year":"2015","journal-title":"Periodontol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0330","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1084\/jem.20061738","article-title":"IL-25 regulates Th17 function in autoimmune inflammation","volume":"204","author":"Kleinschek","year":"2007","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0335","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104095_bb0340","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.celrep.2016.07.075","article-title":"Nrf2 induces IL-17D to mediate tumor and virus surveillance","volume":"16","author":"Saddawi-Konefka","year":"2016","journal-title":"Cell Rep"},{"issue":"15","key":"10.1016\/j.autrev.2026.104095_bb0345","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.18632\/aging.204208","article-title":"Interleukin-17D promotes lung cancer progression by inducing tumor-associated macrophage infiltration via the p38 MAPK signaling pathway","volume":"14","author":"Lin","year":"2022","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0350","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.4049\/jimmunol.181.4.2799","article-title":"The human IL-17F\/IL-17A heterodimeric cytokine signals through the IL-17RA\/IL-17RC receptor complex","volume":"181","author":"Wright","year":"2008","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0355","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.194.4.519","article-title":"Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense","volume":"194","author":"Ye","year":"2001","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0360","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4049\/jimmunol.177.1.36","article-title":"Cutting edge: interleukin 17 signals through a heteromeric receptor complex","volume":"177","author":"Toy","year":"2006","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104095_bb0365","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.immuni.2020.02.004","article-title":"Structural analysis reveals that the cytokine IL-17F forms a Homodimeric complex with receptor IL-17RC to drive IL-17RA-independent signaling","volume":"52","author":"Goepfert","year":"2020","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0370","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/cmi.2010.5","article-title":"Th17 cells and their associated cytokines in liver diseases","volume":"7","author":"Lafdil","year":"2010","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0375","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaut.2008.11.001","article-title":"Hepatic IL-17 responses in human and murine primary biliary cirrhosis","volume":"32","author":"Lan","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104095_bb0380","doi-asserted-by":"crossref","DOI":"10.1007\/s12026-024-09515-3","article-title":"Investigation of the relationship of tissue-resident \u03b3\u03b4 T cells and IL-17 gene expression with the pathogenesis of autoimmune hepatitis","author":"Yucel","year":"2024","journal-title":"Immunol Res"},{"issue":"11","key":"10.1016\/j.autrev.2026.104095_bb0385","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1042\/CS20110496","article-title":"IL-17\/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential","volume":"122","author":"Zhu","year":"2012","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0390","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2024-001596","article-title":"Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study","volume":"12","author":"Elzubeir","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.autrev.2026.104095_bb0395","article-title":"IL-17 signaling in primary sclerosing cholangitis patient-derived organoids","author":"Garcia Moreno","year":"2023","journal-title":"Res Sq"},{"issue":"2","key":"10.1016\/j.autrev.2026.104095_bb0400","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2249.2009.03947.x","article-title":"Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis","volume":"157","author":"Harada","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104095_bb0405","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jhep.2012.07.008","article-title":"CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver","volume":"57","author":"Oo","year":"2012","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104095_bb0410","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/hep4.2001","article-title":"Spatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis","volume":"6","author":"Chung","year":"2022","journal-title":"Hepatol Commun"},{"issue":"599","key":"10.1016\/j.autrev.2026.104095_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3107","article-title":"A biliary immune landscape map of primary sclerosing cholangitis reveals a dominant network of neutrophils and tissue-resident T cells","volume":"13","author":"Zimmer","year":"2021","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104095_bb0420","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ajpath.2013.07.019","article-title":"IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis","volume":"183","author":"O\u2019Brien","year":"2013","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104095_bb0425","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1053\/j.gastro.2018.02.019","article-title":"Alterations in intestinal microbiota lead to production of interleukin 17 by intrahepatic \u03b3\u03b4 T-cell receptor-positive cells and pathogenesis of cholestatic liver disease","volume":"154","author":"Tedesco","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2026.104095_bb0430","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jhep.2021.03.016","article-title":"Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4(+) T cells in primary Sclerosing Cholangitis","volume":"75","author":"Poch","year":"2021","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0435","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2023.11.283","article-title":"Cholangiocytes modulate cluster of differentiation 100 expression in the liver and facilitate pathogenic T-helper 17 cell differentiation","volume":"166","author":"Jiang","year":"2023","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.autrev.2026.104095_bb0440","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.1800455","article-title":"Bidirectional cross-talk between biliary epithelium and Th17 cells promotes local Th17 expansion and bile duct proliferation in biliary liver diseases","volume":"203","author":"Jeffery","year":"2019","journal-title":"J Immunol"},{"issue":"14","key":"10.1016\/j.autrev.2026.104095_bb0445","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0450","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jhep.2009.01.023","article-title":"Influence of dominant bile duct stenoses and biliary infections on outcome in primary Sclerosing Cholangitis","volume":"51","author":"Rudolph","year":"2009","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0455","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000156","article-title":"Biliary microbial patterns in primary sclerosing cholangitis are linked to poorer transplant-free survival","volume":"7","author":"\u00d6zdirik","year":"2023","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.autrev.2026.104095_bb0460","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/hep.26447","article-title":"Increased T helper type 17 response to pathogen stimulation in patients with primary Sclerosing Cholangitis","volume":"58","author":"Katt","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0465","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/hep.31140","article-title":"Monocytes as potential mediators of pathogen-induced T-helper 17 differentiation in patients with primary Sclerosing Cholangitis (PSC)","volume":"72","author":"Kunzmann","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104095_bb0470","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0475","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39029-9","article-title":"Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis","volume":"14","author":"Ichikawa","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0480","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/hep.24307","article-title":"Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9","volume":"53","author":"Janse","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104095_bb0485","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2009.11.046","article-title":"Genome-wide association analysis in primary sclerosing cholangitis","volume":"138","author":"Karlsen","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0490","article-title":"Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis","volume":"14","author":"Han","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.autrev.2026.104095_bb0495","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.05.049","article-title":"Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice","volume":"143","author":"Meng","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2026.104095_bb0500","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jss.2013.03.025","article-title":"Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice","volume":"183","author":"Hara","year":"2013","journal-title":"J Surg Res"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0505","doi-asserted-by":"crossref","first-page":"9922","DOI":"10.18632\/oncotarget.14266","article-title":"Antagonism of interleukin-17A ameliorates experimental hepatic fibrosis by restoring the IL-10\/STAT3-suppressed autophagy in hepatocytes","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0510","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jhep.2020.10.035","article-title":"IL-17A\/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression","volume":"74","author":"Stein","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2026.104095_bb0515","article-title":"PD-1\/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease","volume":"14","author":"Kocheise","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0520","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e6","article-title":"IL-17-producing cells in tumor immunity: friends or foes?","volume":"20","author":"Kuen","year":"2020","journal-title":"Immune Netw"},{"issue":"9","key":"10.1016\/j.autrev.2026.104095_bb0525","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/nm.2015","article-title":"A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses","volume":"15","author":"Wu","year":"2009","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0530","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-10-2907","article-title":"Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer","volume":"71","author":"Tosolini","year":"2011","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0535","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/s41591-023-02372-x","article-title":"Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis","volume":"29","author":"Shaw","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0540","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12016-019-08764-7","article-title":"Cholangiocarcinoma in patients with primary Sclerosing cholangitis (PSC): a comprehensive review","volume":"58","author":"Song","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104095_bb0545","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/ijc.34350","article-title":"Cholangiocarcinoma cell proliferation is enhanced in primary sclerosing cholangitis: a role for IL-17A","volume":"152","author":"Lieshout","year":"2023","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.autrev.2026.104095_bb0550","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2008.12.033","article-title":"Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients","volume":"50","author":"Zhang","year":"2009","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104095_bb0555","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/hep4.1926","article-title":"A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis","volume":"6","author":"Carey","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.autrev.2026.104095_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156587","article-title":"Dual blockade of interleukin-17A and interleukin-17F as a therapeutic strategy for liver fibrosis: investigating the potential effect and mechanism of brodalumab","volume":"178","author":"Matsuda","year":"2024","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0565","doi-asserted-by":"crossref","first-page":"6746","DOI":"10.5826\/dpc.1601a6746","article-title":"Hepatic safety of IL-17 inhibitors in psoriasis and psoriatic arthritis: a 12-month retrospective cohort evaluation using the FIB-4 index","volume":"16","author":"Bakay","year":"2026","journal-title":"Dermatol Pract Concept"},{"issue":"2","key":"10.1016\/j.autrev.2026.104095_bb0570","first-page":"1","article-title":"Brodalumab: a review of safety","volume":"23","author":"Rusta-Sallehy","year":"2018","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.autrev.2026.104095_bb0575","author":"Electronic Medicines Compendium"},{"issue":"10","key":"10.1016\/j.autrev.2026.104095_bb0580","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1007\/s13555-025-01497-w","article-title":"Brodalumab: seven-year US pharmacovigilance report","volume":"15","author":"Lebwohl","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0585","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-018-0888-4","article-title":"Brodalumab: a review in moderate to severe plaque psoriasis","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2026.104095_bb0590","series-title":"COSENTYX\u00ae(secukinumab) Injection, for Subcutaneous Use. Highlights of prescribing Information","author":"Food, Administration D","year":"2015"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0595","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40257-017-0254-4","article-title":"Ixekizumab: a review in moderate to severe plaque psoriasis","volume":"18","author":"Syed","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.autrev.2026.104095_bb0600","author":"Electronic Medicines Compendium"},{"key":"10.1016\/j.autrev.2026.104095_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108402","article-title":"The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases","volume":"102","author":"Berry","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104095_bb0610","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40265-024-02026-3","article-title":"Bimekizumab: a review in psoriatic arthritis","volume":"84","author":"Nie","year":"2024","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.autrev.2026.104095_bb0615","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/1744666X.2023.2277266","article-title":"Bimekizumab for the treatment of psoriatic arthritis","volume":"20","author":"Tanaka","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0620","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0625","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02208-w","article-title":"Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis","volume":"22","author":"Yin","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0630","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104095_bb0635","series-title":"LiverTox: Clinical and research information on drug-induced liver injury","author":"Brodalumab","year":"2012"},{"key":"10.1016\/j.autrev.2026.104095_bb0640","series-title":"LiverTox: Clinical and research information on drug-induced liver injury","author":"Ixekizumab","year":"2012"},{"key":"10.1016\/j.autrev.2026.104095_bb0645","series-title":"LiverTox: Clinical and research information on drug-induced liver injury","author":"Secukinumab","year":"2012"},{"key":"10.1016\/j.autrev.2026.104095_bb0650","author":"Electronic Medicines Compendium"},{"issue":"11","key":"10.1016\/j.autrev.2026.104095_bb0655","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/gut.2011.238477","article-title":"Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease","volume":"60","author":"Kim","year":"2011","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.autrev.2026.104095_bb0660","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/ibd.20475","article-title":"IL-23\/IL-17 immunity as a hallmark of Crohn\u2019s disease","volume":"14","author":"H\u00f6ltt\u00e4","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0665","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2026.104095_bb0670","article-title":"The role of Th17 cells in inflammatory bowel disease and the research progress","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104095_bb0675","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2249.2010.04093.x","article-title":"The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease","volume":"160","author":"Sugihara","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104095_bb0680","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.20071978","article-title":"Regulation of inflammatory responses by IL-17F","volume":"205","author":"Yang","year":"2008","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104095_bb0685","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clim.2003.09.013","article-title":"Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice","volume":"110","author":"Ogawa","year":"2004","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104095_bb0690","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/01.MIB.0000218764.06959.91","article-title":"Critical role of IL-17 receptor signaling in acute TNBS-induced colitis","volume":"12","author":"Zhang","year":"2006","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104095_bb0695","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0700","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40257-019-00466-2","article-title":"Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with Brodalumab for 5 years in a long-term, open-label, phase II study","volume":"20","author":"Lebwohl","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"14","key":"10.1016\/j.autrev.2026.104095_bb0705","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing Brodalumab with Ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2026.104095_bb0710","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/gutjnl-2012-302525","article-title":"Seventeen in Crohn\u2019s disease: less prime than we thought?","volume":"61","author":"Raine","year":"2012","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.autrev.2026.104095_bb0715","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2012-304154","article-title":"Secukinumab failure in Crohn\u2019s disease: the yeast connection?","volume":"62","author":"Colombel","year":"2013","journal-title":"Gut"},{"issue":"10342","key":"10.1016\/j.autrev.2026.104095_bb0720","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.autrev.2026.104095_bb0725","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.crohns.2012.09.016","article-title":"Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study","volume":"7","author":"Herrlinger","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104095_bb0730","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ecco-jcc\/jjad206","article-title":"Risankizumab induction therapy achieves early symptom improvements that are associated with future clinical and endoscopic outcomes in Crohn\u2019s disease: post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY phase 3 studies","volume":"18","author":"Colombel","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"26","key":"10.1016\/j.autrev.2026.104095_bb0735","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104095_bb0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233781","article-title":"Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis","volume":"15","author":"Burisch","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.autrev.2026.104095_bb0745","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.15397","article-title":"Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents","volume":"50","author":"Yamada","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104095_bb0750","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-014-0562-8","article-title":"Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis","volume":"14","author":"Rupp","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104095_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2022.09.006","article-title":"Bile duct colonization with Enterococcus sp. associates with disease progression in Primary Sclerosing Cholangitis","volume":"21","author":"Zigmond","year":"2023","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:29:47Z","timestamp":1790494187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":151,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1568997226001096"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104095","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Interleukin-17-T helper 17 axis in primary sclerosing cholangitis: A narrative review of an emerging pathogenic frontier","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104095"}}